We have always known bumetanide to be an extremely potent and fast-acting, powerful loop diuretic used in managing oedema associated with CHF, hepatic diseases, renal diseases and various nephrotic syndromes. This bumetanide has been administered IV or orally, but then, how about giving it intranasally?
Enbumyst is a newly developed and recently FDA-approved single-use intranasal spray that delivers bumetanide through the intranasal route and has demonstrated similar effects on diuresis, natriuresis and urinary potassium excretion as compared to the oral and IV route.
By avoiding reliance on GI absorption, it offers an alternative in patients where:
-
Oral absorption may be unreliable
-
IV access may not be readily available
-
Outpatient stabilisation is the goal
Using a device platform similar to certain FDA-approved emergency intranasal therapies, Enbumyst is designed for ease of use in different care settings, potentially supporting care continuity outside the hospital.
However, as with all loop diuretics, safety remains central:
-
Risk of fluid, electrolyte and metabolic abnormalities
-
Possible dehydration and hypovolemia
-
Ototoxicity
This, like its other formulations, remains contraindicated in anuria, hepatic coma and hypersensitivity to bumetanide.
Innovation is exciting, but pharmacovigilance is essential.
As future healthcare professionals, do you think intranasal diuretics could meaningfully reduce hospital admissions for fluid overload, or will IV therapy remain the gold standard?
For further information, do read:
https://enbumyst.com/
https://www.drugs.com/enbumyst.html
MBH/AB